Biochip reader GENETRON 3D approved to facilitate tumor liquid biopsy

A biochip reader, known as GENETRON 3D, was officially approved for the Chinese market by the country's drug authorities at the end of 2017.

Currently, many domestic hospitals and scientific research institutions have purchased the product for the development and scientific research of oncogene detection reagent.

The GENETRON 3D biochip reader by the Genetron Health based in Beijing can clearly process and analyze data of special digital PCR chip which has completed the PCR amplified reaction, and without the limitation of matched kit.

Both human EGFR gene T790M mutation test kit under application and registration and similar detection kit under development by Genetron Health can be used together with this reader.

The reader can be applied in medical institutions, clinical laboratories and scientific research institutions, etc. to further effectively improve the detection scope, quality and speed.

Except for the detection of matched tumor liquid biopsy ctDNA, it can also be used for the analysis of viral load, detection of low content pathogene, prenatal screening and diagnosis, analysis of gene expression, verification of the 2nd generation of sequencing result and analysis of methylation level.

Without manual analysis needing complex operations, it can direct read the detection result.

The digital PCR technology is one of the most sensible mutation detection methods, and its sensitivity can reach 0.1%.

As is known to all, the liquid biopsy is regarded as the dramatic breakthrough in the cancer diagnosis field.

Along with cell sorting, high-throughput sequencing, single-cell sequencing, digital PCR, microfluidics and other technologies gradually develop and become mature and the digital PCR technology shows its huge potential in scientific research and application of tumor.

Based on the biochip reader, Genetron Health develops detection solutions against various cancers and sample types, in order to expand its application ranges.

Especially in the liquid biopsy field, the detections against lung cancer, breast cancer, colorectal cancer, stomach cancer and other cancers have been developed.